TTP and OS were significantly lower among patients whose tumours carried KRAS mutations (3.1 vs. 6.4 months, p = 0.001 and 10.6 vs. 16.3 months, p = 0.026, respectively) (Figure 2A and 2B). Similarly, TTP and OS were significantly lower among patients whose tumours carried BRAF mutations (2.1 vs. 5.2 months, p = 0.001 and 4.3 vs. 15.1 months, p<0.0001, respectively) (Figure 3 and 4). There was no significant correlation in terms of TTP according to PIK3CA mutational status or PTEN expression in all treated patients (4.9 vs. 5. This evidence concerns the gene PTEN and neoplasm.